Nasopharyngeal Carcinoma

H9935; Administration of EBV-Specific T-Lymphocytes to Patients with EBV-Positive Nasopharyngeal Carcinoma: This study uses autologous EBV specific T-Lymphocytes to treat nasopharyngeal carcinoma.

H20996: Administration of LMP1 and LMP2 Specific Cytotoxic T Lymphocytes Following CD45 Antibody Administration to Patients with EBV-Positive Nasopharyngeal Carcinoma: This study uses EBV specific T cells in combination with a monoclonal antibody to treat patients with EBV positive NPC.

H21000: Administration Of LMP1- And LMP-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Nasopharyngeal Carcinoma: This study uses EBV specific T cells to treat patients with EBV positive NPC.

 

©2002, Cell And Gene Therapy, Baylor College of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy Email:cagt@bcm.edu
(Modified: September 21st, 2007 - jb)